Albright F, Reifenstein E C. The Parathyriod Glands and Metabolic Bone Disease [J]. The Parathyriod Glands and Metabolic Bone Disease, 1948.
Bao Y, Gao Y, Du M, et al. Topical treatment with Xiaozheng Zhitong Paste (XZP) alleviates bone destruction and bone cancer pain in a rat model of prostate cancer-induced bone pain by modulating the RANKL/RANK/OPG signaling [J]. Evidence-Based Complementary and Alternative Medicine, 2015.
Barros N M T, Hoac B, Neves R L, et al. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X‐linked hypophosphatemia [J]. Journal of Bone and Mineral Research, 2013, 28(3): 688-699.
Basle M F, Mazaud P, Malkani K, et al. Isolation of osteoclasts from pagetic bone tissue morphometry and cytochemistry on isolated cells [J]. Bone, 1988, 9(1): 1-6.
Bhansali A. Metabolic bone disease: Newer perspectives [J]. Indian journal of endocrinology and metabolism, 2012, 16(Suppl 2): S140.
Bischi G I, Chiarella C, Kopel M, et al. Overview and Directions for Future Research[M]//Nonlinear Oligopolies. Springer, Berlin, Heidelberg, 2010: 271-274.
Boukpessi T, Gaucher C, Léger T, et al. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine-and aspartate-rich motif peptide in human hypophosphatemic dentin[J]. The American journal of pathology, 2010, 177(2): 803-812.
Boukpessi T, Hoac B, Coyac B R, et al. Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia [J]. Bone, 2017, 95: 151-161.
Boyce A M, Florenzano P, de Castro L F, et al. Fibrous dysplasia/McCune-Albrightsyndrome[M]//GeneReviews®[Internet]. University of Washington, Seattle, 2018.
Boyce A M, Kelly M H, Brillante B A, et al. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone[J]. The Journal of Clinical Endocrinology & Metabolism, 2014, 99(11): 4133-4140.
Cabral C E L, Guedes P, Fonseca T, et al. Polyostotic fibrous dysplasia associated with intramuscular myxomas: Mazabraud’s syndrome [J]. Skeletal radiology, 1998, 27(5): 278-282.
Cardillo G, Merlini L, Nasini G, et al. Constituents of Dragon's blood. Part I. Structure and absolute configuration of new optically active flavans [J]. Journal of the Chemical Society C: Organic, 1971: 3967-3970.
Carlin B I, Andriole G L. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma[J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2000, 88(S12): 2989-2994.
Cathomas R, Bajory Z, Bouzid M, et al. Management of bone metastases in patients with castration-resistant prostate cancer[J]. Urologia internationalis, 2014, 92(4): 377-386.
Collin-Osdoby P, Yu X, Zheng H, et al. RANKL-mediated osteoclast formation from murine RAW 264.7 cells[M]//Bone research protocols. Humana Press, 2003: 153-166.
Conte P F, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens[J]. The Oncologist, 2004, 9(Supplement 4): 28-37.
Corral D A, Amling M, Priemel M, et al. Dissociation between bone resorption and bone formation in osteopenic transgenic mice[J]. Proceedings of the National Academy of Sciences, 1998, 95(23): 13835-13840.
Darnay B G, Haridas V, Ni J, et al. Characterization of the intracellular domain of receptor activator of NF-κB (RANK) Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase[J]. Journal of Biological Chemistry, 1998, 273(32): 20551-20555.
Davidson-Hunt I. Ecological ethnobotany: stumbling toward new practices and paradigms. MASA J, 16, 2000, 1-13.
Dearnaley D P, Sydes M R, Mason M D, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)[J]. Journal of the National Cancer Institute, 2003, 95(17): 1300-1311.
DiCaprio M R, Enneking W F. Fibrous dysplasia: pathophysiology, evaluation, and treatment[J]. JBJS, 2005, 87(8): 1848-1864.
Gonzales G F, Valerio L G. Medicinal plants from Peru: a review of plants as potential agents against cancer[J]. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2006, 6(5): 429-444.
Gralow J R, Biermann J S, Farooki A, et al. NCCN task force report: bone health in cancer care[J]. Journal of the National Comprehensive Cancer Network, 2009, 7(Suppl_3): S-1-S-32.
e Lopes M I L, Saffi J, Echeverrigaray S, et al. Mutagenic and antioxidant activities of Croton lechleri sap in biological systems[J]. Journal of Ethnopharmacology, 2004, 95(2-3): 437-445.
Gupta D, Bleakley B, Gupta R K. Dragon's blood: botany, chemistry and therapeutic uses[J]. Journal of ethnopharmacology, 2008, 115(3): 361-380.
Harley R D. Artists' pigments, c. 1600-1835; a study in English documentary sources[J]. 1982.
Hsieh T P, Sheu S Y, Sun J S, et al. Icariin isolated from Epimedium pubescens regulates osteoblasts anabolism through BMP-2, SMAD4, and Cbfa1 expression[J]. Phytomedicine, 2010, 17(6): 414-423.
Hsu H, Lacey D L, Dunstan C R, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand[J]. Proceedings of the National Academy of Sciences, 1999, 96(7): 3540-3545.
Ishida N, Hayashi K, Hoshijima M, et al. Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator[J]. Journal of Biological Chemistry, 2002, 277(43): 41147-41156.
Jain N, Weinstein R S. Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges[J]. Nature Reviews Rheumatology, 2009, 5(6): 341.
Karsenty G, Wagner E F. Reaching a genetic and molecular understanding of skeletal development[J]. Developmental cell, 2002, 2(4): 389-406.
Kawai M, Rosen C J. The insulin-like growth factor system in bone: basic and clinical implications[J]. Endocrinology and Metabolism Clinics, 2012, 41(2): 323-333.
Keller J, Brink S, Busse B, et al. Divergent resorbability and effects on osteoclast formation of commonly used bone substitutes in a human in vitro-assay[J]. PloS one, 2012, 7(10): e46757.
Kong Y Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis[J]. Nature, 1999, 397(6717): 315.
Kozyrakis D, Paridis D, Perikleous S, et al. The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer[J]. Advances in urology, 2018, 2018
Lee J S, FitzGibbon E J, Chen Y R, et al. Clinical guidelines for the management of craniofacial fibrous dysplasia[C]//Orphanet journal of rare diseases. BioMed Central, 2012, 7(1): S2.
Lei S F, Chen Y, Xiong D H, et al. Ethnic difference in osteoporosis-related phenotypes and its potential underlying genetic determination[J]. Journal of Musculoskeletal and Neuronal Interactions, 2006, 6(1): 36.
Liu J, Shiono J, Tsuji Y, et al. Methyl ganoderic acid DM: a selective potent osteoclastogenesis inhibitor[J]. The Open Bioactive Compounds Journal, 2009, 2(1).
Lu S H, Chen T H, Chou T C. Magnolol Inhibits RANKL-induced osteoclast differentiation of raw 264.7 macrophages through heme oxygenase-1-dependent inhibition of NFATc1 expression[J]. Journal of natural products, 2015, 78(1): 61-68.
Manolagas S C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis[J]. Endocrine reviews, 2000, 21(2): 115-137.
McInnes I B, Schett G. The pathogenesis of rheumatoid arthritis[J]. New England Journal of Medicine, 2011, 365(23): 2205-2219.
McKee M D, Hoac B, Addison W N, et al. Extracellular matrix mineralization in periodontal tissues: Noncollagenous matrix proteins, enzymes, and relationship to hypophosphatasia and X‐linked hypophosphatemia[J]. Periodontology 2000, 2013, 63(1): 102-122.
Mohamed S G K, Sugiyama E, Shinoda K, et al. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264. 7 cells and mouse bone marrow cells[J]. Bone, 2007, 41(4): 592-602.
Miyamoto I, Liu J, Shimizu K, et al. Regulation of osteoclastogenesis by ganoderic acid DM isolated from Ganoderma lucidum[J]. European journal of pharmacology, 2009, 602(1): 1-7.
Muralidharan A, Smith M T. Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments[J]. Inflammopharmacology, 2013, 21(5): 339-363.
Notelovitz M. Osteoporosis: screening, prevention, and management[J]. Fertility and sterility, 1993, 59(4): 707-725.
Palmieri C, Fullarton J R, Brown J. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis[J]. Clinical Cancer Research, 2013, 19(24): 6863-6872.
Paul Tuck S, Layfield R, Walker J, et al. Adult Paget’s disease of bone: a review [J]. Rheumatology, 2017, 56(12): 2050-2059.
Plotkin H, Rauch F, Zeitlin L, et al. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone[J]. The Journal of Clinical Endocrinology & Metabolism, 2003, 88(10): 4569-4575.
Raisz L G, Rodan G A. Pathogenesis of osteoporosis[J]. Endocrinology and metabolism clinics of North America, 2003, 32(1): 15-24.
Ralston S H, Layfield R. Pathogenesis of Paget disease of bone [J]. Calcified tissue international, 2012, 91(2): 97-113.
Rodan G A, Fleisch H A. Bisphosphonates: mechanisms of action[J]. The Journal of clinical investigation, 1996, 97(12): 2692-2696.
Rogers M J, Gordon S, Benford H L, et al. Cellular and molecular mechanisms of action of bisphosphonates[J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2000, 88(S12): 2961-2978.
Rosen L S, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of
multiple myeloma: a phase III, double-blind, comparative trial[J]. Cancer journal (Sudbury, Mass.), 2001, 7(5): 377-387.
Ross F P. M‐CSF, c‐Fms, and signaling in osteoclasts and their precursors[J]. Annals of the New York Academy of Sciences, 2006, 1068(1): 110-116.
Rossi D, Bruni R, Bianchi N, et al. Evaluation of the mutagenic, antimutagenic and antiproliferative potential of Croton lechleri (Muell. Arg.) latex[J]. Phytomedicine, 2003, 10(2-3): 139-144.
Saraswathy A, Vidhya B. (+)-Afzelechin from the rhizome of Calamus rotang Linn[J]. Indian drugs, 2012, 49(49): 49-50.
Sato K, Takayanagi H. Osteoclasts, rheumatoid arthritis, and osteoimmunology[J]. Current opinion in rheumatology, 2006, 18(4): 419-426.
Simonet W S, Lacey D L, Dunstan C R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J]. cell, 1997, 89(2): 309-319.
Smith M R, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial[J]. The Lancet, 2012, 379(9810): 39-46.
Sukari S, Said I M. Phenolic Compounds from the Fruits of Orania Sylvicola[J]. Malaysian Journal of Analytical Sciences, 2013, 17(2): 276-280.
Syafni N, Putra D P, Arbain D. 3, 4-dihydroxybenzoic acid and 3, 4-dihydroxybenzaldehyde from the fern Trichomanes chinense L.; isolation, antimicrobial and antioxidant properties[J]. Indonesian Journal of Chemistry, 2012, 12(3): 273-278.
Takayanagi H. The role of NFAT in osteoclast formation[J]. Annals of the New York Academy of Sciences, 2007, 1116(1): 227-237.
Tan H, Furuta S, Nagata T, et al. Inhibitory effects of the leaves of loquat (Eriobotrya japonica) on bone mineral density loss in ovariectomized mice and osteoclast differentiation [J]. Journal of agricultural and food chemistry, 2014, 62(4): 836-841.
Teitelbaum S L, Ross F P. Genetic regulation of osteoclast development and function[J]. Nature Reviews Genetics, 2003, 4(8): 638. Vincent C, Kogawa M, Findlay D M, et al. The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions[J]. Journal of bone and mineral metabolism, 2009, 27(1): 114-119.
Wada T, Nakashima T, Hiroshi N, et al. RANKL–RANK signaling in osteoclastogenesis and bone disease[J]. Trends in molecular medicine, 2006, 12(1): 17-25.
Wagner E F, Karsenty G. Genetic control of skeletal development[J]. Current opinion in genetics & development, 2001, 11(5): 527-532.
Wu Y B, Zheng C J, Qin L P, et al. Antiosteoporotic activity of anthraquinones from Morinda officinalis on osteoblasts and osteoclasts[J]. Molecules, 2009, 14(1): 573-583.
Yamashita T, Yao Z, Li F, et al. NF-kB p50 and p52 regulate RANKL and TNF-induced osteoclast precursor differentiation by activating c-Fos and NFATc1[J]. Journal of Biological Chemistry, 2007.
Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL[J]. Proceedings of the National Academy of Sciences, 1998, 95(7): 3597-3602.
Yokoyama S, Bang T H, Shimizu K, et al. Osteoclastogenesis inhibitory effect of ergosterol peroxide isolated from Pleurotus eryngii[J]. Natural product communications, 2012, 7(9): 1934578X1200700913.
Zhang G, Qin L, Hung W Y, et al. Flavonoids derived from herbal Epimedium Brevicornum Maxim prevent OVX-induced osteoporosis in rats independent of its enhancement in intestinal calcium absorption[J]. Bone, 2006, 38(6): 818-825.
Zhang D, Zhang J, Fong C, et al. Herba epimedii flavonoids suppress osteoclastic differentiation and bone resorption by inducing G2/M arrest and apoptosis[J]. Biochimie, 2012, 94(12): 2514-2522.
ZHAO X, FENG Y, Yong P. Prevention and treatment of osteoporosis with Chinese herbal medicines[J]. Chinese Herbal Medicines, 2012, 4(4): 265-270.
https://en.wikipedia.org/wiki/Paget%27s_disease_of_bone#cite_note-22
https://www.niams.nih.gov/health-topics/osteoporosis
https://rarediseases.info.nih.gov/diseases/5700/rickets
https://rarediseases.org/rare-diseases/rickets-vitamin-d-deficiency/
論文の公開元へ
